Medical Vaccine Supply – Typhoid VI Polysaccharide Vaccine

The contract entails the supply of 20,000 units of FDA-approved, preservative-free Typhoid VI Polysaccharide Vaccine specifically for U.S. military personnel, ensuring compliance with strict medical and safety standards. The vaccine is intended for use in active-duty service members and is being procured under a subcontract arrangement, with the Defense Logistics Agency acting on behalf of the Department of Defense to fulfill operational needs. The contract is structured to support potential future orders under an Indefinite-Delivery, Indefinite-Quantity framework, allowing for scaled procurement based on evolving mission requirements without requiring new bidding processes. All units must meet regulatory requirements for purity and stability, with no preservatives included to accommodate sensitive immunological profiles. The performance location and delivery specifications are not fully detailed, but the vaccine will be distributed to U.S. military installations domestically and potentially overseas to support force readiness and disease prevention initiatives. The North American Industry Classification System code 325412 confirms the product falls under pharmaceutical and medicine manufacturing. The contract was posted in July 2026, indicating procurement activity is already underway, and the unique contract identifier links to official DLA documentation for tracking fulfillment and logistics coordination. This acquisition reflects a strategic priority to secure biologics that are both effective and compliant with military health protocols.